Home › Peripheral Nerve Disorders › Pennsylvania › Philadelphia
Peripheral Nerve Disorders clinical trials in Philadelphia, PA
3 studies for Peripheral Nerve Disorders are looking for participants at sites in and around Philadelphia (within about 30 miles). Open a study to see who can join and how to contact the study team.
Recruiting for a study here? Feature it at the top of this page — $99 for 30 days →
This Study Will Evaluate the Effectiveness of NTX-001, a Surgical Nerve Repair Product When Used in People With Upper Extremity Nerve Lacerations.
RecruitingPhase 3
- University of Pennsylvania, Department of Orthopaedic Surgery, Philadelphia
A Comparison of NeuroSpan Bridge, NeuraGen Nerve Guide, and Nerve Autograft for Peripheral Nerve Repair
Recruiting
- University of Pennsylvania- Penn Presbyterian Medical Center, Philadelphia
Optimizing Integrative Oncology Approaches to Address Chemotherapy-induced Peripheral Neuropathy in Gastrointestinal (GI) Cancer Patients: A SMART Pilot Study
Recruiting
- Sidney Kimmel Cancer Center at Thomas Jefferson University, Philadelphia
About Peripheral Nerve Disorders
Peripheral nerves are nerves outside your brain and spinal cord. Learn about neuropathy and more than 100 other types of peripheral nerve disorders.
More about Peripheral Nerve Disorders on MedlinePlus
Peripheral Nerve Disorders trials in other cities
- New York City, NY5 studies
- Orlando, FL4 studies
- Baltimore, MD4 studies
- Boston, MA4 studies
- Washington, DC3 studies
- Chicago, IL3 studies
- Pittsburgh, PA3 studies
- San Francisco, CA3 studies
- St. Louis, MO3 studies
- Columbia, MO3 studies
Other studies in Philadelphia
- Cancer (all types)57 studies
- Breast Cancer51 studies
- Non-Small Cell Lung Cancer49 studies
- Ovarian Cancer47 studies
- Metastatic Cancer42 studies
- Colorectal Cancer41 studies
- Prostate Cancer41 studies
- Lung Cancer36 studies
- Acute Myeloid Leukemia33 studies
- Heart Failure31 studies
- Endometrial Cancer29 studies
- Pancreatic Cancer26 studies
From ClinicalTrials.gov, data retrieved Nov 15, 2026. Each study sets its own eligibility; the study team decides who can join.